Clinical trials: PSA Progression, open to volunteers
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)
The primary objective of this study is to measure efficacy of saruparib + physician's choice of ARPI compared with placebo + ARPI in men with metastatic hormone-sensitive prostate cancer (mHSPC) who have previously received…
- Trial name
- EvoPAR-PR05 (NCT07711002)
- Testing
- Saruparib, Enzalutamide, Darolutamide
- Where
- 210 sites in United States, Austria and 19 more
- Volunteers
- 1,330 people
- Sponsor
- AstraZeneca
PSA Progression, PSA
MRI-Assisted Guidance for Non-Essential Tissue Sampling
The study aims to determine if a less painful and less invasive prostate biopsy approach is safe for certain men with a high risk of prostate cancer.
- Trial name
- NCT07516223
- Testing
- Paired Prostate Biopsy Cohort (TB + SB)
- Where
- China
- Volunteers
- 1,235 people
- Sponsor
- Shanghai East Hospital
Prostate Cancer
Multiparametric Magnetic Resonance Imaging of the Prostate to Assess Disease Progression and Genomics in Patients Undergoing Active Surveillance for Prostate Cancer
Background: Active surveillance (AS) is a standard approach to treat low and intermediate risk prostate cancer. For AS, disease progression is monitored.
- Trial name
- NCT04692675
- Testing
- mpMRI
- Where
- United States
- Volunteers
- 508 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Safety and Efficacy of AGN-INM176 in Prostate Patients With Rising PSA
This Phase I/II open-label trial aims to evaluate the safety and efficacy of the herbal supplement INM176 in patients with a history of prostate cancer or low-risk disease under active surveillance.
- Trial name
- NCT06600698
- Testing
- INM176
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Milton S. Hershey Medical Center
Inflammatory Joint Diseases, Rheumatoid Arthritis (RA)
Oxidative Stress in Autoimmune Rheumatic Diseases
Rheumatic diseases constitute a group of non-communicable diseases characterized by chronic inflammation. The most common autoimmune rheumatic diseases (ARDs) are rheumatoid arthritis, psoriatic arthritis, systemic lupus…
- Conditions
- Inflammatory Joint Diseases, Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS)
- Trial name
- REDOX-ARD (NCT07536529)
- Where
- Greece
- Volunteers
- 200 people
- Sponsor
- University of Thessaly
Metastatic Castration-Resistant Prostate Cancer, mCRPC
REGN21353 Alone or in Combination With Nezastomig for Metastatic Castration-Resistant Prostate Cancer in Adult Participants
This study will test an experimental Regeneron drug called REGN21353 ("study drug") to see if it can help treat previously treated prostate cancer that has spread (also called metastatic castration-resistant prostate cancer or…
- Trial name
- NCT07850921
- Testing
- REGN21353, Nezastomig, Sarilumab Prophylaxis (Contingency)
- Volunteers
- 192 people
- Sponsor
- Regeneron Pharmaceuticals
Prostate Cancer (Post Prostatectomy)
PET Scan Study to Detect Prostate Cancer in Patients with Early PSA Recurrence
Flotufolastat F-18, sold under the brand name Posluma, is a radioactive diagnostic agent for use with positron emission tomography (PET) imaging for prostate cancer.
- Trial name
- NCT06617481
- Testing
- 18F-rhPSMA-7.3 (Posluma)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- AdventHealth
Metastatic Prostate Cancer
Talazoparib Plus Enzalutamide After Progression to Prior ARPi in Metastatic Prostate Cancer
The purpose of this clinical trial is to determine the anti-tumor activity of talazoparib plus enzalutamide as first line treatment for metastatic castration resistant prostate cancer (mCRPC) in participants whose disease has…
- Trial name
- TEAM PC (NCT06582628)
- Testing
- Enzalutamide capsule, Enzalutamide capsule and Talazoparib capsule
- Where
- 19 sites in France, Spain
- Volunteers
- 78 people
- Sponsor
- Fundacion Oncosur
Prostate Cancer
Prostate Risk Or Radiology Assessment Non-inferiority Design, Upfront MRI or Risk Calculator in Men With Suspected Prostate Cancer
Thousands of men take a PSA test to investigate whether they have prostate cancer every year. For the vast majority, the test is normal and further investigations are not necessary.
- Trial name
- PRORAND (NCT07422597)
- Testing
- European Study of screening for prostate cancer risk calculator
- Where
- 3 sites in Norway
- Volunteers
- 1,016 people, healthy volunteers welcome
- Sponsor
- Norwegian University of Science and Technology
Prostate Cancer, Elevated PSA
Upright MRI for Prostate Cancer Screening
This is an investigator initiated study to test the efficacy of an upright MRI (Magnetic Resonance Imaging) for the screening of prostate cancer.
- Conditions
- Prostate Cancer, Elevated PSA, Elevated Prostate Specific Antigen
- Trial name
- NCT03474913
- Testing
- Upright MRI, Standard MRI
- Where
- United States
- Volunteers
- 550 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Metastatic Castration-resistant Prostate Cancer
The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
The purpose of this study is to evaluate the efficacy and safety of 177Lu-TLX591 in patients with metastatic castration-resistant prostate cancer who have progressed following treatment with Androgen Receptor Pathway Inhibitor…
- Trial name
- NCT06520345
- Testing
- 177Lu-TLX591, Enzalutamide, Abiraterone
- Where
- 33 sites in United States, Australia and 4 more
- Volunteers
- 520 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Suspected Prostate Cancer (increased PSA Level)
Oncological Prognosis of Prostate Lesions by Chemical Exchange Saturation Transfer Magnetic Resonance Imaging (CEST-MRI)
Prostate cancer is the second most common type of cancer in men only after lung cancer, and accounts for ~3.8% of all deaths caused in men in 2018.
- Trial name
- ProstaCEST (NCT06669273)
- Testing
- CEST MRI sequence at 3T
- Where
- France
- Volunteers
- 70 people
- Sponsor
- University Hospital, Clermont-Ferrand
Psoriatic Arthritis
A Study of Zasocitinib in Adults With Psoriatic Arthritis (LATITUDE PsA NeXt)
Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasis (PsO).
- Trial name
- NCT07871721
- Testing
- Zasocitinib
- Volunteers
- 644 people
- Sponsor
- Takeda
Prostate Cancer
Working Out M0 Bipolar Androgen Therapy
The WOMBAT study will test if BAT can prolong the time it takes for nmCRPC prostate cancer to become detectable in other areas of the body (metastatic disease).
- Trial name
- WOMBAT (NCT06594926)
- Testing
- Testosterone Enanthate
- Where
- 12 sites in Australia
- Volunteers
- 69 people
- Sponsor
- Australian and New Zealand Urogenital and Prostate Cancer Trials Group